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Abstract  
Background: We aimed to evaluate the effect of sarcopenia, a condition of low muscle mass, on the 
survival among patients who were undergoing radical nephroureterectomy (RNU) for urothelial 
carcinoma of the upper urinary tract (UCUT). 
Methods: We retrospectively reviewed consecutive patients with UCUT (cT[any]N0M0) who 
underwent RNU between 2003 and 2013 at our department and its affiliated institutions. Preoperative 
computed tomography images were used to calculate each patient’s skeletal muscle index, an indicator 
of whole-body muscle mass. Sarcopenia was defined according to the sex-specific consensus 
definitions, based on the patient’s skeletal muscle and body mass indexes. We analyzed the relapse-
free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) after RNU to identify 
factors that predicted patient survival.  
Results: A total of 137 patients were included, and 90 patients (65.7%) were diagnosed with sarcopenia. 
Compared to the non-sarcopenic patients, the sarcopenic patients had a significant inferior 5-year RFS 
(48.8% vs. 79.6%, p = 0.0002), CSS (57.1% vs. 92.6%, p < 0.0001), and OS (48.2% vs. 90.6%, p < 
0.0001). Multivariate analyses revealed that sarcopenia was an independent predictor of shorter RFS, 
CSS, and OS (all, p < 0.0001).  
Conclusions: Sarcopenia was an independent predictor of survival among patients with UCUT who 
were undergoing RNU. 
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Introduction 
Sarcopenia is a state of degenerative skeletal muscle wasting, and has recently been recognized as an 
important physiological change that occurs during the development of cancer cachexia [1,2]. 
Sarcopenia is associated with a poor physical condition [3], reduced tolerance of anti-cancer therapy 
[4,5], more frequent surgical complications [6-10], and poorer patient survival [8,11-13]. Although 
sarcopenia occurs during normal aging, it can be exacerbated by the hypercatabolic state and 
inflammatory response that are caused by malignancy [14]. The diagnosis of sarcopenia is confirmed 
using sex-specific consensus definitions that were suggested in a study of a large Canadian cohort, 
based on the combination of skeletal muscle and body mass indexes that are calculated using imaging 
findings [1]. These methods provide an objective subclinical measurement of patient frailty and 
nutritional status, and can be used to gauge an individual’s physical condition.  
Sarcopenia can affect patient survival, even in localized cancers (i.e., no metastasis) if the tumor was 
removed using curative therapy [13,15-17], although patients with localized cancers are thought to be 
less affected by cachexia, compared to patients with advanced cancers. In addition, the association 
between sarcopenia and survival has been reported among patients with urothelial carcinoma (UC). 
Nevertheless, there were few studies regarding the correlation between sarcopenia and survival among 
patients who are undergoing radical nephroureterectomy (RNU) for UC of the upper urinary tract 
(UCUT).  
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This retrospective multi-institution study aimed to investigate the effect of sarcopenia on survival 
among a cohort of patients with localized UCUT who were undergoing RNU.  
 
Materials and methods 
The internal Ethics Review Board of Tokyo Women’s Medical University- Aoyama Hospital Tokyo 
Women’s Medical University (ID: 3696), and Saiseikai Kawaguchi General Hospital (ID: 27-11) 
approved this retrospective study’s protocol. The study was performed in accordance with the 
principals that are outlined in the Declaration of Helsinki. Between October 2003 and December 2013, 
we performed RNU for 238 patients with non-metastatic UCUT (cT[any]N0M0) at our department 
and its affiliated institutions. However, the present study excluded patients who had received 
hemodialysis therapy (n = 11), who had prior UC (n = 41), or who had received neoadjuvant 
chemotherapy (n = 11). We also excluded patients with missing preoperative imaging data (n = 9) or 
missing follow-up data (n = 32). Thus, 137 patients were included in the present study (Figure 1).  
Clinical and laboratory data were extracted from an electronic database and the patients’ medical 
records. Staging of the tumor was performed according to the Union for International Cancer Control 
TNM classification [18]. The preoperative stage was determined based on computed tomography 
findings, and all preoperative imaging was performed within 2 months before the surgery. Surgery was 
performed based on the procedure for the management of urothelial tumors of the renal pelvis and 
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ureter, as described in Campbell’s Urology [19]. Open standard nephroureterectomy and 
retroperitoneoscopic surgery were performed in conjunction with open distal ureter and bladder cuff 
removal at our institutions. All tumors were confirmed to be UC using histology.  
 
Imaging methods and definitions of sarcopenia  
 The cross-sectional areas of the lumbar skeletal muscle complement (including the rectus abdominus; 
bilateral internal, external, and lateral obliques; psoas; quadratus lumborum; and erector spinae) were 
identified using attenuation thresholds of -29 Hounsfield units (HU) and +150 HU with a Toshiba 
Aquilion 64 multidetector scanner (Toshiba, Tochigi, Japan). Manual scripting was used to define the 
area of interest at each 1-mm level, and the areas of interest were then summed. L3 was set as a 
landmark, and the mean value for two consecutive images was computed for each patient and 
normalized for stature: skeletal muscle index (SMI) (cm2/m2) = (skeletal muscle cross-sectional area 
at L3)/ (height2) [11,20]. SMI was assessed as a continuous variable, and used as an indicator of whole-
body muscle mass, as a previous study has demonstrated that the total lumbar-skeletal muscle cross-
sectional area is linearly correlated with whole-body muscle mass [21]. Based on the international sex-
specific consensus definitions of sarcopenia, we stratified the patients as sarcopenic and non-
sarcopenic according to their body mass index (BMI), using a threshold lumbar SMI of < 43 cm2/m2 
among men with a BMI of <25 kg/m2, < 53 cm2/m2 among men with a BMI of >25 kg/m2, and < 41 
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cm2/m2 among women [1]. All imaging analyses were performed by one investigator (HI) who was 
blinded to the other clinical parameters and patient outcomes. 
 
Protocol for regional lymphadenectomy    
We simultaneously performed regional lymphadenectomy (LND; named template-based LND) with 
the RNU for patients with cT[any]N0M0 UCUT, except for patients with severe comorbidities or at 
an advanced age [22,23]. The right renal hilar, paracaval, retrocaval, and interaortocaval nodes were 
dissected for tumors of the right pelvis and tumors of the right upper and middle ureter. The left renal 
hilar and para-aortic nodes were dissected for tumors of the left renal pelvis and tumors of the left 
upper and middle ureter. The lower boundary of the template was defined as the level of the inferior 
mesenteric artery for pelvic tumors, and as the aortic bifurcation for upper and middle ureter tumors. 
The ipsilateral common iliac, external iliac, obturator, and internal iliac nodes were included for 
tumors of the lower ureter. Dissection of the presacral nodes was not necessary for patients with lower 
ureteral cancer. All LNDs were performed as an open procedure, and the lymph node specimens were 
sampled en bloc with the surrounding adipose tissue.  
 
Adjuvant chemotherapy 
 Adjuvant chemotherapy was considered when we observed nodal involvement and/or disease 
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infiltrating the surrounding adipose tissue. However, the final decision was made based on the patients’ 
comorbidities, performance status, and willingness to receive chemotherapy. Chemotherapy consisted 
of 1-3 cycles of methotrexate, vinblastine, doxorubicin, and cisplatin, or 1-3 cycles of gemcitabine 
and cisplatin. 
 
Perioperative complications 
 Perioperative complications were evaluated up to 90 days after surgery, and were graded using the 
Clavien-Dindo classification [24]. 
 
Statistical analysis 
Continuous variables were analyzed using the Mann-Whitney U-test, and categorical variables were 
analyzed using the χ2 test or Fisher’s exact test. Relapse-free survival (RFS), cancer-specific survival 
(CSS), and overall survival (OS) after RNU were calculated using the Kaplan-Meier method, and 
compared between the sarcopenic and non-sarcopenic patients, respectively. To clarify the association 
between tumor stages and sarcopenia, the potential of sarcopenia as a prognostic factor was assessed 
according to tumor stage (pT and pN) based on Kaplan-Meier survival curves. We performed 
multivariate analyses to identify factors that were associated with RFS, CSS, and OS using Cox 
proportional hazards regression models. RFS was defined as the time from the RNU to the first 
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instance of local recurrence, metastasis, or death due to any cause. CSS and OS were defined as the 
time from the RNU to death due to cancer-related causes or any cause, respectively. Risk was 
expressed as the hazard ratio (HR) with 95% confidence interval (CI). All analyses were performed 
using the JMP software (version 11; SAS Institute Inc., Cary, NC, USA), and differences with a p-
value of < 0.05 were considered statistically significant. 
 
Results 
Patient characteristics  
The patients’ characteristics are summarized in Table 1. Ninety patients were sarcopenic (65.7%). 
The sarcopenic patients were significantly older (mean age: 75.3 years vs. 68.5 years, p < 0.0001), and 
were significantly more likely to be female (46.7% vs. 12.8%, p < 0.0001), compared to the non-
sarcopenic patients. The sarcopenic patients also exhibited a significantly shorter height (1.58 m vs. 
1.63 m, p = 0.0015), lighter weight (55.6 kg vs. 64.6 kg, p < 0.0001), lower BMI (22.2 kg/m2 vs. 24.1 
kg/m2, p < 0.0001), smaller skeletal muscle area (90.4 cm2 vs. 129.3 cm2, p < 0.0001), and lower SMI 
(35.8 cm2/m2 vs. 48.1 cm2/m2, p<0.0001). However, when we compared the sarcopenic and non-
sarcopenic patients, there were no significant differences in the tumor site, LND status, pT stage, pN 
stage, tumor grade, frequency of adjuvant chemotherapy, or Charlson comorbidity index (all, p > 0.05).  
The sarcopenic patients exhibited a significantly shorter follow-up period (mean follow-up: 36.5 
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months vs. 58.0 months, p < 0.0001). During the follow-up, tumor recurrence or metastasis was 
observed in 50 patients (36.5%), and the numbers of deaths due to cancer or any cause were 35 (25.6%) 
and 43 (31.4%), respectively. These rates were significantly higher among the sarcopenic patients 
(RFS: p = 0.0007; CSS: p = 0.0001; OS: p < 0.0001). 
 
Patient survival  
 Figure 2 shows the Kaplan-Meier curves for patient survival after RNU according to sarcopenia 
status. Sarcopenia was associated with a significantly shorter RFS (5-year survival: 48.8 % vs. 79.6 %, 
p = 0.0002), CSS (57.1 % vs. 92.6 %, p < 0.0001), and OS (48.2 % vs. 90.6 %, p < 0.0001). Figure 3 
shows Kaplan-Meier survival curves according to pT stage and sarcopenia status. The results indicated 
that for 26 non-sarcopenic patients with tumor stage < pT3, 34 sarcopenic patients with stage < pT3, 
21 non-sarcopenic patients with stage ≥ pT3, and 56 sarcopenic patients with stage ≥ pT3, the 5-year 
RFS rates were 95.7%, 87.5%, 62.6%, and 25.4%, respectively; the 5-year CSS rates were 100.0%, 
82.4%, 83.1%, and 39.3%, respectively; and the 5-year OS rates were 100.0%, 70.6%, 79.2%, and 
32.4%, respectively. Among the 60 patients with tumor stage < pT3, sarcopenia was significantly 
associated with inferior OS (p = 0.0120), whereas among the 77 patients with tumor stage ≥ pT3, 
sarcopenia was significantly associated with inferior RFS, CSS, and OS (p = 0.0025, 0.0008, 0.0007, 
respectively). Figure 4 shows Kaplan-Meier survival curves according to the pN stage and sarcopenia 
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status. For 41 non-sarcopenic patients with tumor stage pNx or 0, 83 sarcopenic patients with stage 
pNx or 0, 6 non-sarcopenic patients with stage ≥ pN1, and 7 sarcopenic patients with stage ≥ pN1, the 
3-year RFS rates were 92.3%, 53.2%, 22.2%, and 0.00%, respectively; the 5-year CSS rates were 
97.2%, 60.6%, 40.0%, and 0.00%, respectively; and the 5-yaer OS rates were 97.2%, 51.2%, 33.3%, 
and 0.00%, respectively. Among the 124 patients with tumor stage pNx or 0, sarcopenia was 
significantly associated with inferior RFS, CSS, and OS (all, p < 0.0001), whereas among the 13 
patients with tumor stage ≥ pN1, sarcopenia was significantly associated with inferior CSS (p = 
0.0331). 
 
Perioperative complications   
 The perioperative complications according to sarcopenia status are shown in Table 2. Perioperative 
complications were observed in 11 of the 90 sarcopenic patients (12.2%), compared to in 7 of the 47 
non-sarcopenic patients (14.9%). Two sarcopenic patients and 2 non-sarcopenic patients experienced 
Grade ≥3 complications. One sarcopenic patient underwent drainage under radiographic guidance for 
lymphorrhea (Grade 3a), and the other sarcopenic patient received an ileus tube under radiographic 
guidance (Grade 3a). One non-sarcopenic patient underwent colostomy for a rectum perforation 
(Grade 3b), the other non-sarcopenic patient underwent surgical drainage and hemodialysis for severe 
renal failure due to sepsis that was caused by a retroperitoneal abscess (Grade 4). There were no 
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significant differences in the rates of all-grade or Grade ≥3 perioperative complications (p = 0.607 and 
p = 0.66, respectively). 
 
Predictors of patient survival 
 Multivariate analyses revealed that sarcopenia was an independent predictor of shorter RFS (HR: 
5.18, p < 0.0001), CSS (HR: 13.3, p < 0.0001), and OS (HR: 12.1, p < 0.0001). The pT and pN stages 
were also independent predictors of all endpoints (all, p < 0.05). Moreover, a LND status was an 
independent predictor of longer OS (HR: 2.22, p = 0.0380) (Table 3). 
 
Discussion 
 To our knowledge, this multi-institution retrospective study is the first to evaluate the relationship 
between sarcopenia and survival outcomes among patients who were undergoing RNU for UCUT. We 
found that sarcopenia was significantly associated with poor patient survival, although there were no 
significant differences in the rates of perioperative complications when we compared the sarcopenic 
and non-sarcopenic patients.  
 Recent studies have suggested that sarcopenia is a novel biomarker for survival among patients with 
malignancies. In this context, malignancy can result in a hypercatabolic state that is caused by tumor 
metabolism, systematic inflammation, and other tumor-mediated effects [25]. When combined with 
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other cancer-mediated effects, such as anorexia, fatigue, decreased functional status, and immobility, 
this hypercatabolic state can lead to the depletion of skeletal muscle and the development of sarcopenia. 
Furthermore, sarcopenia may have an effect on survival among patients with advanced or metastatic 
cancers [5,26-29]. For example, Sharma et al. [27] reported that sarcopenia predicted OS after 
cytoreductive nephrectomy for metastatic renal cell carcinoma, and Prado et al. [5] reported that 
sarcopenia predicted toxicity and time to tumor progression among patients with metastatic breast 
carcinoma who were treated using chemotherapy. Interestingly, this effect is also observed in localized 
cancers [15-17], which are thought to exhibit less severe inflammatory responses or nutritional 
disorders, compared to advanced or metastatic cancers. Moreover, recent studies have reported that 
sarcopenia was associated with both tumor relapse (i.e., RFS or disease-free survival) and mortality 
outcomes, such as CSS [15,17] or OS [13,15,17], among patients who were undergoing curative 
surgery. However, only a few studies have examined the effect of sarcopenia on RFS or disease-free 
survival. Harimoto et al. [13] observed decreased RFS among sarcopenic patients who were 
undergoing curative partial hepatectomy for hepatocellular carcinoma. Similarly, Miyamoto et al. [16] 
reported that sarcopenia negatively affected survival among patients who were undergoing curative 
resection for stage I-III colorectal cancer. Furthermore, our data revealed that sarcopenia was 
significantly correlated with RFS, CSS, and OS among patients with UCUT who were undergoing 
curative surgery. Although these results are interesting, they are difficult to explain. One possible 
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explanation is that sarcopenia may be induced by a systematic inflammatory response or nutritional 
disorder, and may directly promote or accelerate tumor progression or dissemination. Thus, sarcopenic 
patients may have micrometastases that cannot be detected using routine radiological examinations. 
Moreover, experimental investigations have revealed inflammatory and immune cells in tumors, such 
as dendritic cells, macrophages, and lymphocytes, which produced cytokines and other factors that 
promoted tumor growth and affected survival [30-32].  
Sarcopenia can predict survival outcomes in UC, as Psutka et al. [15] reported that sarcopenia 
significantly increased the risk of mortality after radical cystectomy for bladder cancer. Furthermore, 
other groups have also reported that sarcopenia was an independent biomarker among patients with 
advanced or metastatic UC, which included bladder carcinoma or UCUT [26,29]. Moreover, 
Fukushima et al. [26] suggested that sarcopenia was a useful predictor of shorter OS in advanced or 
metastatic UC (UCUT and bladder carcinoma combined). These results agree with our findings that 
sarcopenia was an independent predictor of survival after RNU for localized UCUT, after we adjusted 
for well-known risk factors, such as pT and pN [33-35].  
We also found that the prognostic potential of sarcopenia as a survival biomarker was higher for more 
invasive UCUT. Thus, the association between sarcopenia and survival tended to be stronger for 
patients with higher pT stage (≥ pT3) (Table 3); however, the significance of an association between 
sarcopenia and pN stage could not be statistically evaluated because of a small number of patients 
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with tumor stage ≥ pN1. We speculate that patient’s age may be a factor, since the present study 
included some patients with low stage cancer (i.e., pTa or 1), for whom sarcopenia could have been 
induced by age-related physiological changes rather than cancer. The distinction between age-related 
and cancer-mediated sarcopenia is important but difficult to detect because the sarcopenic status may 
be affected by a combination of various factors such as aging, cancer-mediated chronic inflammation, 
and treatment-associated fatigue. The multivariate analysis showed that statistical significance of 
sarcopenia as a prognostic factor remained after adjusting for age; however, further studies separately 
evaluating the impact of age-related and cancer-mediated sarcopenia are needed.  
The present study has several limitations. First, we used a retrospective design, which limits the level 
of provided evidence, and the analyzed patient population was small. Second, the retrospective design 
precludes any analysis of other parameters of muscle mass wasting (i.e., cachexia), such as history of 
weight loss [1], or reduced walking speed or grip strength [36], which are common symptoms of 
cachexia and are significantly associated with outcomes [1,6]. Third, we used BMI-adjusted cut-off 
values for SMI to define sarcopenia, which were established in a Canadian patient cohort [1]. However, 
it is not clear whether these values are accurate when they are used in a non-Canadian population. 
Therefore, future studies may be needed to identify the appropriate SMI cut-off values for the Japanese 
population. Furthermore, prospective studies are needed to validate the predictive value of sarcopenia, 
and to account for other parameters of cachexia, among patients with UCUT who are undergoing RNU.  
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Conclusions 
Sarcopenia was an independent predictor of survival among patients with localized UCUT who were 
undergoing RNU. The advantage of this parameter is that sarcopenia can be easily evaluated without 
extra cost or effort, as it is quantified using routine imaging tests. Moreover, we found that sarcopenia 
remained an independent predictor after adjustment for tumor staging factors (pT and pN) and age. 
Therefore, this new biomarker may effectively predict the outcome of UCUT before performing 
surgery. Nevertheless, careful follow-up is needed to monitor the postoperative course of patients with 
sarcopenia.   
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Figure legends 
Figure 1: Flow-chart for the present study. RNU, radical nephroureterectomy; UCUT, urothelial 
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carcinoma of the upper urinary tract; UC, urothelial carcinoma 
 
Figure 2: Kaplan-Meier estimates of (a) relapse-free survival, (b) cancer-specific survival, and (c) 
overall survival according to sarcopenia status among 137 patients with urothelial carcinoma of the 
upper urinary tract (cT[any]N0M0).  
Red and blue lines represent patients with and without sarcopenia, respectively.  
 
Figure 3: Kaplan-Meier estimates of (a) relapse-free survival, (b) cancer-specific survival, and (c) 
overall survival according to the pT stage and sarcopenia status among 137 patients with urothelial 
carcinoma of the upper urinary tract (cT[any]N0M0).  
Blue, red, yellow, and green lines represent patients with stage < pT3 without sarcopenia (n = 26), 
stage < pT3 with sarcopenia (n = 34), stage ≥ pT3 without sarcopenia (n = 21), and stage ≥ pT3 with 
sarcopenia (n = 56), respectively. RNU, radical nephroureterectomy  
 
Figure 4: Kaplan-Meier estimates of (a) relapse-free survival, (b) cancer-specific survival, and (c) 
overall survival according to the pN stage sarcopenia status among 137 patients with urothelial 
carcinoma of the upper urinary tract (cT[any]N0M0).  
Blue, red, yellow, and green lines represent patients with stage pNx or 0 without sarcopenia (n = 41), 
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stage pNx or 0 with sarcopenia (n = 83), stage ≥ pN1 without sarcopenia (n = 6), and stage ≥ pN1 with 
sarcopenia (n = 7), respectively. RNU, radical nephroureterectomy 
Figure 1: Flow-chart for the present study
Patients undergoing RNU for UCUT with 
cT[any]N0M0 between 2003 October and 2013 
December (n = 238)
178 patients
Patients were excluded:
• Receiving hemodialysis therapy (n = 11)
• Had prior UC (n = 41) 
• Receiving neoadjuvant chemotherapy (n = 8)
The remaining 137 patients 
were analyzed
Patients were excluded:
• Missing preoperative imaging data (n = 9)
• Missing follow-up data (n = 32)
Table 1: Patient characteristics
Variable All (n = 137) With sarcopenia (n = 90) Without sarcopenia (n = 47) p
Mean age, years (median, range) 72.8 (73.0, 39-92) 75.3 (78.0, 39-92) 68.5 (70.0, 52.0-87.0) <0.0001
Sex
Male
Female
89 (65.0%)
48 (35.0%)
48 (53.3%)
42 (46.7%)
41 (87.2%)
6 (12.8%)
<0.0001
Sites of  tumor
Pelvis
Ureter
79 (57.7%)
58 (42.3%)
50 (55.6%)
40 (44.4%)
29 (61.7%)
18 (38.3%)
0.586
LND
Yes
No
54 (39.4%)
83 (60.6%)
32 (35.6%)
58 (64.4%)
22 (46.8%)
25 (53.2%)
0.269
pT stage
< pT3
≥ pT3
60 (43.8%)
77 (56.2%)
34 (37.8%)
56 (62.2%)
26 (55.3%)
21 (44.7%)
0.0693
pN stage
pNx or 0
≥ pN1
124 (90.5%)
13 (9.49%)
83 (92.2%)
7 (7.78%)
41 (87.2%)
6 (12.8%)
0.368
Grade of tumor
Low grade
High grade 
34 (24.8%)
103 (75.2%)
19 (21.1%)
71 (78.9%)
15 (31.9%)
32 (68.1%)
0.211
Mean height, m (median, range) 1.60 (1.61, 1.33-1.85) 1.58 (1.57, 1.38-1.85) 1.63 (1.64, 1.33-1.8) 0.0015
Mean weight, kg (median, range) 58.7 (57.0, 32-98.4) 55.6 (55.0, 32.0-81.0) 64.6 (63.0, 45.6-98.4) <0.0001
Mean BMI, kg/m2 (median, range) 22.8 (22.7, 14.4-32.9) 22.2 (22.0, 14.4-31.8) 24.1 (23.8, 17.5-32.9) <0.0001
Mean skeletal muscle area, cm2 (median, range) 103.7 (100.0, 38.7-202.9) 90.4 (84.4, 38.7-151.8) 129.3 (130.0, 81.5-202.9) <0.0001
Mean SMI, cm2/m2 (median, range) 40.0 (40.6, 20.3-67.3) 35.8 (34.8, 20.3-50.7) 48.1 (46.1, 41.0-67.3) <0.0001
Adjuvant chemotherapy 
Yes 
No
16 (11.7%)
121 (88.3%)
12 (13.3%)
78 (86.7%)
4 (8.51%)
43 (91.5%)
0.577
Charlson comorbidity index
< 3
≥ 3
122 (89.0%)
15 (11.0%)
80 (88.9%)
10 (11.1%)
42 (89.4%)
5 (10.6%)
1.000
Mean follow-up period, months (median, range) 43.9 (34.7, 2.83-140.3) 36.5(26.7, 2.83-129.8) 58.0 (49.2, 10.4-140.3) <0.0001
Tumor recurrence or metastasis 
Yes
No
50 (36.5%)
87 (63.5%)
42 (46.7%)
48 (53.3%)
8 (17.0%)
39 (83.0%)
0.0007
Died from cancer
Yes 
No
35 (25.6%)
102 (74.5%)
32 (35.6%)
58 (64.4%)
3 (6.38%)
44 (93.6%)
0.0001
Died from any cause
Yes  
No
43 (31.4%)
94 (68.6%)
39 (43.3%)
51 (56.7%)
4 (8.51%)
43 (91.5%)
<0.0001
LND, lymphadenectomy; CIS, carcinoma in situ; LVI, lymphovascular invasion; CRP, C-reactive protein; BMI, body mass index; SMI, skeletal muscle index;  
Figure 2: Kaplan-Meier estimates of (a) relapse-free survival, (b) cancer-specific survival, and (c) overall 
survival according to sarcopenia status among 137 patients with urothelial carcinoma of the upper urinary 
tract (cT[any]N0M0)
5-year survivalSarcopenia
status 
Yes (n = 90)
No (n = 47)
48.8 %
79.6 %
p = 0.0002
5-year survival
57.1 %
92.6 %
p < 0.0001
5-year survival
48.2 %
90.6 %
p < 0.0001
(a) (b) (c)
Figure 3: Kaplan-Meier estimates of (a) relapse-free survival, (b) cancer-specific survival, and (c) 
overall survival according to the pT stage and sarcopenia status among 137 patients with urothelial 
carcinoma of the upper urinary tract (cT[any]N0M0)
5-year survivalpT stage
with/without sarcopenia
< pT3 without sarcopenia (n =26)
< pT3 with sarcopenia (n = 34)
95.7 %
87.5 %
5-year survival
100.0 %
82.4 %
5-year survival
100.0 %
70.6 %
(a) (b) (c)
≥ pT3 without sarcopenia (n = 21)
≥ pT3 with sarcopenia (n = 56)
62.6 %
25.4 %
83.1 %
39.3 %
79.2 %
32.4 %
p = 0.0025 p = 0.0008 p = 0.0007
p = 0.245 p = 0.0688 p = 0.0120
Figure 4: Kaplan-Meier estimates of (a) relapse-free survival, (b) cancer-specific survival, and (c) 
overall survival according to the pN stage and sarcopenia status among 137 patients with urothelial 
carcinoma of the upper urinary tract (cT[any]N0M0)
3-year survivalpN stage
with/without sarcopenia
pNx or 0 without sarcopenia (n = 41)
pNx or 0 with sarcopenia (n = 83)
92.3 %
53.2 %
5-year survival
97.2 %
60.6 %
5-year survival
97.2 %
51.2 %
(a) (b) (c)
≥ pN1 without sarcopenia (n = 6)
≥ pN1 with sarcopenia (n = 7)
22.2 %
0.00 %
40.0 %
0.00 %
33.3 %
0.00 %
p < 0.0001p < 0.0001p < 0.0001
p = 0.0901 p = 0.0331 p = 0.109
Clavien-Dindo
classification 
All (n = 137) With sarcopenia (n = 90) Without sarcopenia (n = 47) p
Grade 1
Femoral nerve paralysis
Bleeding
Lymphorrhea
Others 
8 (5.84%)
2 (1.46%)
2 (1.46%)
1 (0.73%)
3 (2.19%)
5 (5.56%)
1 (1.11%) 
2 (2.22%)
1 (1.11%)
1 (1.11%)
3 (6.38%)
1 (2.13%)
0
0
2 (4.26%)
Grade 2
Bleeding 
Infection 
Ileus 
6 (4.38%)
3 (2.19%)
2 (1.46%)
1 (0.73%)
4 (4.44%)
3 (3.33%)
1 (1.11%)
0
2 (4.26%)
0
1 (2.13%)
1 (2.13%)
Grade 3a
Lymphorrhea
Ileus
2 (1.46%)
1 (0.73%)
1 (0.73%)
2 (2.22%)
1 (1.11%) 
1 (1.11%)
0
0
0
Grade 3b
Rectal perforation 1 (0.73%) 0 1 (2.13%)
Grade 4a
Retroperitoneal abscess 1 (0.73%) 0 1 (2.13%)
Incidence (all grades) 18 (13.1%) 11 (12.2%) 7 (14.9%) 0.66
Incidence (grade ≥3) 4 (2.92%) 2 (2.22%) 2 (4.26%) 0.607
Table 2: Perioperative complications according to sarcopenia status
Table 3: Multivariate analyses of relapse-free survival, cancer-specific survival, and overall survival among137 patients with urothelial 
carcinoma of the upper urinary tract (cT[any]N0M0)
RFS
HR (95% CI) p
CSS
HR (95% CI) p
OS
HR (95% CI) p
Age 0.99 (0.95 – 1.02) 0.490 1.00 (0.96 – 1.05) 0.859 1.01 (0.97 – 1.06) 0.504
LND
Yes
No 
Ref.
1.89 (0.95 – 3.84)
-
0.0712
Ref.
1.72 (0.76 – 4.03)
-
0.192
Ref.
2.22 (1.04 – 4.94)
-
0.0380
pT
< pT3
≥ pT3
Ref.
6.15 (2.47 – 18.8)
-
<0.0001
Ref.
5.21 (1.79 – 19.6)
-
0.0015
Ref.
3.78 (1.55 – 10.4)
-
0.0028
pN
pNx or 0
≥ pN1
Ref.
7.45 (3.27 – 16.5)
-
<0.0001
Ref.
8.58 (2.92 – 23.9)
-
0.0002
Ref.
9.25 (3.42 – 23.8)
-
<0.0001
Grade of tumor
Low grade
High grade
Ref.
3.10 (0.85 – 20.0)
-
0.0923
Ref.
2.34 (0.58 – 15.8)
-
0.252
Ref.
1.23 (0.42 – 4.13)
-
0.717
Sarcopenia
Yes
No
5.18 (2.36 – 12.7)
Ref.
<0.0001 13.3 (4.10 – 61.7)
Ref.
<0.0001 12.1 (4.31 – 44.2)
Ref.
<0.0001
-
RFS, relapse-free survival; CSS, cancer-specific survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; LND, lymphadenectomy
Table 1: Patient characteristics 
 
Variable All (n = 137) With sarcopenia (n = 90) Without sarcopenia (n = 47) p 
Mean age, years (median, range) 72.8 (73.0, 39-92) 75.3 (78.0, 39-92) 68.5 (70.0, 52.0-87.0) <0.0001 
Sex 
 Male 
 Female 
 
89 (65.0%) 
48 (35.0%) 
 
48 (53.3%) 
42 (46.7%) 
 
41 (87.2%) 
6 (12.8%) 
<0.0001 
Sites of  tumor 
 Pelvis 
 Ureter 
 
79 (57.7%) 
58 (42.3%) 
  
50 (55.6%) 
40 (44.4%) 
 
29 (61.7%) 
18 (38.3%) 
0.586 
LND 
 Yes 
 No 
 
54 (39.4%) 
83 (60.6%) 
 
32 (35.6%) 
58 (64.4%) 
 
22 (46.8%) 
25 (53.2%) 
0.269 
pT stage 
 < pT3 
 ≥ pT3 
 
60 (43.8%) 
77 (56.2%) 
 
34 (37.8%) 
56 (62.2%) 
 
26 (55.3%) 
21 (44.7%) 
0.0693 
pN stage 
 pNx or 0 
 ≥ pN1 
 
124 (90.5%) 
13 (9.49%) 
 
83 (92.2%) 
7 (7.78%) 
 
41 (87.2%) 
6 (12.8%) 
0.368 
Grade of tumor 
 Low grade 
 High grade  
 
34 (24.8%) 
103 (75.2%) 
 
19 (21.1%) 
71 (78.9%) 
 
15 (31.9%) 
32 (68.1%) 
0.211 
Mean height, m (median, range) 1.60 (1.61, 1.33-1.85) 1.58 (1.57, 1.38-1.85) 1.63 (1.64, 1.33-1.8) 0.0015 
Mean weight, kg (median, range) 58.7 (57.0, 32-98.4) 55.6 (55.0, 32.0-81.0) 64.6 (63.0, 45.6-98.4) <0.0001 
Mean BMI, kg/m2 (median, range) 22.8 (22.7, 14.4-32.9) 22.2 (22.0, 14.4-31.8) 24.1 (23.8, 17.5-32.9) <0.0001 
Mean skeletal muscle area, cm2 (median, range) 103.7 (100.0, 38.7-202.9) 90.4 (84.4, 38.7-151.8) 129.3 (130.0, 81.5-202.9) <0.0001 
Mean SMI, cm2/m2 (median, range) 40.0 (40.6, 20.3-67.3) 35.8 (34.8, 20.3-50.7) 48.1 (46.1, 41.0-67.3) <0.0001 
Adjuvant chemotherapy  
 Yes  
 No 
 
16 (11.7%) 
121 (88.3%) 
 
12 (13.3%) 
78 (86.7%) 
 
4 (8.51%) 
43 (91.5%) 
0.577 
Charlson comorbidity index 
 < 3 
 ≥ 3 
 
122 (89.0%) 
15 (11.0%) 
 
80 (88.9%) 
10 (11.1%) 
 
42 (89.4%) 
5 (10.6%) 
1.000 
Mean follow-up period, months (median, range) 43.9 (34.7, 2.83-140.3) 36.5(26.7, 2.83-129.8) 58.0 (49.2, 10.4-140.3) <0.0001 
Tumor recurrence or metastasis  
 Yes 
 
50 (36.5%) 
 
42 (46.7%) 
 
8 (17.0%) 
0.0007 
 No 87 (63.5%) 48 (53.3%) 39 (83.0%) 
Died from cancer 
 Yes  
 No 
 
35 (25.6%) 
102 (74.5%) 
 
32 (35.6%) 
58 (64.4%) 
 
3 (6.38%) 
44 (93.6%) 
0.0001 
Died from any cause 
 Yes   
 No 
 
43 (31.4%) 
94 (68.6%) 
 
39 (43.3%) 
51 (56.7%) 
 
4 (8.51%) 
43 (91.5%) 
<0.0001 
LND, lymphadenectomy; CIS, carcinoma in situ; LVI, lymphovascular invasion; CRP, C-reactive protein; BMI, body 
mass index; SMI, skeletal muscle index  
 
Table 2: Perioperative complications according to sarcopenia status 
 
Clavien-Dindo classification  All (n = 137) With sarcopenia (n = 90) Without sarcopenia (n = 47) p 
Grade 1 
 Femoral nerve paralysis 
 Bleeding 
 Lymphorrhea 
 Others  
8 (5.84%) 
2 (1.46%) 
2 (1.46%) 
1 (0.73%) 
3 (2.19%) 
5 (5.56%) 
1 (1.11%)  
2 (2.22%) 
1 (1.11%) 
1 (1.11%) 
3 (6.38%) 
1 (2.13%) 
0 
0 
2 (4.26%) 
 
Grade 2 
 Bleeding  
 Infection  
 Ileus  
6 (4.38%) 
3 (2.19%) 
2 (1.46%) 
1 (0.73%) 
4 (4.44%) 
3 (3.33%) 
1 (1.11%) 
0 
2 (4.26%) 
0 
1 (2.13%) 
1 (2.13%) 
 
Grade 3a 
 Lymphorrhea 
 Ileus 
2 (1.46%) 
1 (0.73%) 
1 (0.73%) 
2 (2.22%) 
1 (1.11%)  
1 (1.11%) 
0 
0 
0 
 
Grade 3b 
 Rectal perforation  
 
1 (0.73%) 
 
0 
 
1 (2.13%) 
 
Grade 4a 
 Retroperitoneal abscess 
 
1 (0.73%) 
 
0 
 
1 (2.13%) 
 
Incidence (all grades) 18 (13.1%) 11 (12.2%) 7 (14.9%) 0.66 
Incidence (grade ≥3) 4 (2.92%) 2 (2.22%) 2 (4.26%) 0.607 
 
Table 3: Multivariate analyses of relapse-free survival, cancer-specific survival, and overall 
survival among137 patients with urothelial carcinoma of the upper urinary tract (cT[any]N0M0) 
 
 
RFS 
HR (95% CI) 
p CSS 
HR (95% CI) 
p OS 
HR (95% CI) 
p 
Age  0.99 (0.95 – 1.02) 0.490 1.00 (0.96 – 1.05) 0.859 1.01 (0.97 – 1.06) 0.504 
LND 
 Yes 
 No  
 
Ref. 
1.89 (0.95 – 3.84) 
0.0712  
Ref. 
1.72 (0.76 – 4.03) 
0.192  
Ref. 
2.22 (1.04 – 4.94) 
0.0380 
pT 
 < pT3 
 ≥ pT3 
 
Ref. 
6.15 (2.47 – 18.8) 
<0.0001  
Ref. 
5.21 (1.79 – 19.6) 
0.0015  
Ref. 
3.78 (1.55 – 10.4) 
0.0028 
pN 
 pNx or 0 
 ≥ pN1 
 
Ref. 
7.45 (3.27 – 16.5) 
<0.0001  
Ref. 
8.58 (2.92 – 23.9) 
0.0002  
Ref. 
9.25 (3.42 – 23.8) 
<0.0001 
Grade of tumor 
 Low grade 
 High grade 
 
Ref. 
3.10 (0.85 – 20.0) 
0.0923  
Ref. 
2.34 (0.58 – 15.8) 
0.252  
Ref. 
1.23 (0.42 – 4.13) 
0.717 
Sarcopenia 
 Yes 
 No 
 
5.18 (2.36 – 12.7) 
Ref. 
<0.0001  
13.3 (4.10 – 61.7) 
Ref. 
<0.0001  
12.1 (4.31 – 44.2) 
Ref. 
<0.0001 
RFS, relapse-free survival; CSS, cancer-specific survival; OS, overall survival; HR, hazard ratio; CI, 
confidence interval; LND, lymphadenectomy 
 
